Clinical Cancer Research Targets Advances in Breast Cancer
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Shah, M. H.
Right arrow Articles by Grever, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Shah, M. H.
Right arrow Articles by Grever, M.
Related Collections
Right arrowCommentary
Clinical Cancer Research Vol. 12, 3997-4003, July 1, 2006
© 2006 American Association for Cancer Research


Cancer Therapy: Clinical

Cardiotoxicity of Histone Deacetylase Inhibitor Depsipeptide in Patients with Metastatic Neuroendocrine Tumors

Manisha H. Shah1, Philip Binkley2, Kenneth Chan3, Jim Xiao3, Daria Arbogast1, Minden Collamore1, Yasser Farra2, Donn Young4 and Michael Grever1

Authors' Affiliations: Divisions of 1 Hematology-Oncology and 2 Cardiology, Department of Internal Medicine; 3 Colleges of Pharmacy and Medicine; and 4 Center for Biostatistics, The Ohio State University Comprehensive Cancer Center, Columbus, Ohio

Requests for reprints: Manisha H. Shah, The Ohio State University, A438 Starling-Loving Hall, 320 West 10th Avenue, Columbus, OH 43210. Phone: 614-293-8629; Fax: 614-293-3112; E-mail: manisha.shah{at}osumc.edu.

Purpose: This phase II study was undertaken to assess objective response and toxicity of histone deacetylase inhibitor depsipeptide in patients with neuroendocrine tumors.

Experimental Design: A total of 15 patients with metastatic neuroendocrine tumors received a 4-hour i.v. infusion of depsipeptide at 14 mg/m2 on days 1, 8, and 15 every 28 days. Tumor response was assessed at 8-week intervals using Response Evaluation Criteria in Solid Tumors. Most patients were chemo-naïve (n = 12) but receiving long-acting octreotide for carcinoid syndrome (n = 11). All patients had Eastern Cooperative Oncology Group performance status of 0 to 1.

Results: The study was terminated prematurely due to an unexpected high number of serious cardiac adverse events so the objective response rate could not be determined. A total of 77 doses of depsipeptide with a median of four doses (range, 2-13) per patient were administered. The most common adverse events included nausea (86%), anorexia (73%), vomiting (66%), and fatigue (73%). A sudden death attributed to possible fatal ventricular arrhythmia occurred within 24 hours after the fifth dose of depsipeptide. Furthermore, asymptomatic grade 2 ventricular tachycardia (n = 2) and prolonged QTc (n = 3) probably related to depsipeptide were observed. Plasma depsipeptide levels measured in a subset of patients failed to reveal differences among patients with or without cardiac adverse events.

Conclusions: Depsipeptide was associated with a high number of potentially serious cardiac adverse events in patients with metastatic neuroendocrine tumor. As sudden death possibly associated with depsipeptide was observed in this trial, the risks for potentially life-threatening arrhythmia associated with this agent need to be comprehensively evaluated.


Commentary

Challenges of Evaluating the Cardiac Effects of Anticancer Agents
Susan E. Bates, Douglas R. Rosing, Tito Fojo, and Richard L. Piekarz
Clin. Cancer Res. 2006 12: 3871-3874. [Full Text] [PDF]



This article has been cited by other articles:


Home page
Molecular Cancer TherapeuticsHome page
H. Su, L. Altucci, and Q. You
Competitive or noncompetitive, that's the question: research toward histone deacetylase inhibitors
Mol. Cancer Ther., May 1, 2008; 7(5): 1007 - 1012.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
V. M. Klimek, S. Fircanis, P. Maslak, I. Guernah, M. Baum, N. Wu, K. Panageas, J. J. Wright, P. P. Pandolfi, and S. D. Nimer
Tolerability, Pharmacodynamics, and Pharmacokinetics Studies of Depsipeptide (Romidepsin) in Patients with Acute Myelogenous Leukemia or Advanced Myelodysplastic Syndromes
Clin. Cancer Res., February 1, 2008; 14(3): 826 - 832.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Zhang, D. Lebwohl, E. Masson, G. Laird, M. R. Cooper, and H. M. Prince
Clinically Relevant QTc Prolongation Is Not Associated With Current Dose Schedules of LBH589 (panobinostat)
J. Clin. Oncol., January 10, 2008; 26(2): 332 - 333.
[Full Text] [PDF]


Home page
JCOHome page
E. L. Strevel and L. L. Siu
In Reply
J. Clin. Oncol., January 10, 2008; 26(2): 333 - 334.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
D. S. Schrump, M. R. Fischette, D. M. Nguyen, M. Zhao, X. Li, T. F. Kunst, A. Hancox, J. A. Hong, G. A. Chen, E. Kruchin, et al.
Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Clin. Cancer Res., January 1, 2008; 14(1): 188 - 198.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
E. L. Strevel, D. J. Ing, and L. L. Siu
Molecularly Targeted Oncology Therapeutics and Prolongation of the QT Interval
J. Clin. Oncol., August 1, 2007; 25(22): 3362 - 3371.
[Abstract] [Full Text] [PDF]


Home page
Ann OncolHome page
I Duran, R Salazar, O Casanovas, V Arrazubi, E Vilar, L. Siu, J Yao, and J Tabernero
New drug development in digestive neuroendocrine tumors
Ann. Onc., August 1, 2007; 18(8): 1307 - 1313.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
R. Molife, P. Fong, M. Scurr, I. Judson, S. Kaye, and J. de Bono
HDAC Inhibitors and Cardiac Safety
Clin. Cancer Res., February 1, 2007; 13(3): 1068 - 1068.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
M. H. Shah, M. A. Villalona-Calero, G. Marcucci, J. C. Byrd, and M. R. Grever
HDAC Inhibitors and Cardiac Safety
Clin. Cancer Res., February 1, 2007; 13(3): 1068 - 1068.
[Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. H. Rubin, N. G.B. Agrawal, E. J. Friedman, P. Scott, K. E. Mazina, L. Sun, L. Du, J. L. Ricker, S. R. Frankel, K. M. Gottesdiener, et al.
A Study to Determine the Effects of Food and Multiple Dosing on the Pharmacokinetics of Vorinostat Given Orally to Patients with Advanced Cancer
Clin. Cancer Res., December 1, 2006; 12(23): 7039 - 7045.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
S. E. Bates, D. R. Rosing, T. Fojo, and R. L. Piekarz
Challenges of Evaluating the Cardiac Effects of Anticancer Agents.
Clin. Cancer Res., July 1, 2006; 12(13): 3871 - 3874.
[Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2006 by the American Association for Cancer Research.